Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression

Conclusion
Ticagrelor, unlike clopidogrel, exhibits endothelial-specific antithrombotic properties and blunts arterial thrombus formation. The additional antithrombotic properties displayed by ticagrelor may explain its greater efficacy in reducing thrombotic events in clinical trials. These findings may provide the basis for new indications for ticagrelor.

Source: Cardiovascular Research - January 8, 2017 Category: Cardiology Authors: Reiner, M. F., Akhmedov, A., Stivala, S., Keller, S., Gaul, D. S., Bonetti, N. R., Savarese, G., Glanzmann, M., Zhu, C., Ruf, W., Yang, Z., Matter, C. M., Lüscher, T. F., Camici, G. G., Beer, J. H. Tags: Vascular biology Source Type: research